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Abstract
The impact of genetic variants in telomere pathway genes on telomere length and breast cancer
survival remains unclear. We hypothesized that telomere length and genetic variants of telomere
pathway genes are associated with survival among breast cancer patients. A population-based
cohort study of 1,026 women diagnosed with a first primary breast cancer was conducted to
examine telomere length and 52 genetic variants of 9 telomere pathway genes. Adjusted Cox
regression analysis was employed to examine associations between telomere length, genetic
variants and all-cause and breast cancer-specific mortality. Longer telomere length was
significantly correlated with all-cause mortality in the subgroup with HER-2/neu negative tumors
(HR=1.90, 95%CI: 1.12–3.22). Carrying the PINX1-33 (rs2277130) G-allele was significantly
associated with increased all-cause mortality (HR=1.45, 95% CI: 1.06–1.98). Three SNPs
(TERF2-03 rs35439397, TERT-14 rs2853677 and TERT-67 rs2853669) were significantly
associated with reduced all-cause mortality. A similar reduced trend for breast cancer-specific
mortality was observed for carrying the TERT-14 (rs2853677) T-allele (HR=0.57, 95% CI: 0.39–
0.84), while carrying the POT1-18 (rs1034794) T-allele significantly increased breast cancer
specific-mortality (HR=1.48, 95% CI: 1.00–2.19). However, none of the associations remained
significant after correction for multiple tests. A significant dose-response effect was observed with
increased number of unfavorable alleles/genotypes (PINX1-33 G-allele, POT1-18 T-allele,
TERF2-03 GG, TERT-14 CC, and TERT-67 TT genotypes) and decreased survival. These data
suggest that unfavorable genetic variants in telomere pathway genes may help to predict breast
cancer survival.
Keywords
Genetic variants; telomere length; breast cancer; survival
*Corresponding author: Jing Shen, Department of Environmental Health Sciences, Mailman School of Public Health, Columbia
University, 650 West 168th Street, Black Building 1608, New York, NY 10032, USA, Phone: 212-305-8158, Fax: 212-305-5328,
js2182@columbia.edu.
Competing interests. The authors declare that they have no competing interests.
NIH Public Access
Author Manuscript
Breast Cancer Res Treat. Author manuscript; available in PMC 2013 July 01.
Published in final edited form as:














Breast cancer mortality has modestly decreased among women in the United States during
recent years, but remains the second most common cancer death [1]. Clinical
histopathological characteristics of breast cancer, including tumor size, lymph node status,
metastases, histological grade and type, are important determinants for prognosis [2]. In
addition, molecular markers in several biological pathways, such as estrogen/progesterone
(ER/PR) receptors, HER-2/neu, epidermal growth factor receptor, insulin-like growth factor/
receptor and PI3K/AKT/mTOR also predict breast cancer prognosis and survival (as
reviewed by Morrow [3]). Germline inherited polymorphisms may also play a role in
determining prognosis by influencing host susceptibility to tumor progression and metastasis
[4;5]. Several genetic variations including those in tissue inhibitors of metalloproteinases
(TIMPs) [6], GPX4 in the antioxidant pathway [7], COMT in the steroid hormone
metabolism pathway [8], interleukin-10 (IL-10) [9], and IL-1RN [10] have been reported to
be associated with overall survival among women with breast cancer. However, due to the
biological heterogeneity of breast cancer, further efforts are needed for exploration of novel
biomarkers to identify molecular subgroups of prognostic significance [11;12]. Until now,
little is known about the role of genetic polymorphisms in telomere pathway genes and
telomere length on breast cancer survival.
Telomeres are essential chromosome end structures consisting of tandem repeats of the
TTAGGG sequence, telomerase and a number of associated proteins. The functions of
telomeres are to control cellular proliferation/replication and maintain genomic integrity and
stability [13;14]. Genetic variations that effect telomere elongation, activation of telomerase
and configuration of telomeric proteins could disrupt or reduce these functions, and affect
clinical prognosis or outcome [15–17]. One study has reported that single nucleotide
polymorphisms (SNPs) in telomere pathway genes (TERF2, TNKS and TNKS2) were
associated with high histological grade, negative estrogen receptor status and lymph node
metastases, but not with breast cancer survival during the follow-up period (median of 4.7
years) [17]. Several studies have reported that telomere length in solid tumor tissues may be
a potential prognostic marker (as reviewed by Bisoffi and Svenson [18;19]), and may differ
by tumor type. A recent study revealed that telomere length variation in normal epithelial
cells adjacent to tumor is a strong predictor of breast cancer local recurrence after breast
conserving surgery [20]. Another previous study conducted among 227 breast cancer
patients reported that peripheral blood telomere length may carry significant prognostic
information, and longer telomere length was associated with a worse outcome compared to
shorter telomere length, especially for patients age 50 or younger [16]. Thus, the impact of
common inherited genetic variants in telomere pathway genes on telomere length and breast
cancer survival remains unclear.
In this report, 52 genetic variants in nine key telomere maintenance genes (PINX1, POT1,
RAD18, TERC, TERF1, TERF2, TERF2IP, TERT and TNKS) were tested to evaluate the
hypothesis that genetic variations in telomere pathway genes contain valuable prognostic
information to predict breast cancer survival. The long-term follow-up of the population-
based Long Island Breast Cancer Study Project (LIBCSP) includes outcome data with which
to evaluate this hypothesis.
MATERIALS AND METHODS
Study design and patient population
The study protocol was approved by all institutional review boards of the collaborating
institutions. Detailed study methods of the parent study have been described previously [21–
23].
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The parent LIBCSP included a population-based cohort of 1,508 women diagnosed with
breast cancer. Subjects were identified among adult female residents of Nassau and Suffolk
counties on Long Island, NY, who were any race, age 20 years or older at the time of
diagnosis, spoke English, and were newly diagnosed with a first primary in situ or invasive
breast cancer between August 1, 1996, and July 31, 1997.
Baseline data collection
In-person baseline interviews were conducted by trained personnel within a few months of
each case’s diagnosis. The structured, baseline questionnaire collected information on
known and suspected factors associated with breast cancer. Medical records were abstracted
to obtain hormone receptor status and other clinical characteristics of the first primary
tumor.
Study outcomes
The LIBCSP follow-up study was conducted to obtain vital status among the cohort of
LIBCSP breast cancer participants. The National Death Index was used to ascertain all-
cause and breast cancer-specific mortality. By the end of 2005, a total of 308 (29.1%) deaths
occurred, and 164 (53.2%) deaths were due to breast cancer based on International
Classification of Diseases (ICD) codes 174.9 and C–50.9. The mean follow up time was 8.0
years (range: 0.2~9.4 years).
Biospecimens
Blood samples were donated by 1,102 breast cancer patients at the time of the baseline
interview. Blood was processed using a standard protocol [22], and genomic DNA was
isolated by standard phenol and chloroform/isoamyl alcohol extraction and RNase treatment
as previously described [24]. The current project were restricted to utilizing samples donated
by breast cancer patients with sufficient DNA for measuring telomere pathway markers (n =
1,026). There were 889 cases who donated blood prior to any chemotherapy, while 137
cases provided blood post chemotherapy. The comparisons between two groups of
participants (with and without sufficient DNA samples) found no significant differences in
age at diagnosis, menopausal status, race, body mass index (BMI = weight in kilograms
divided by height in meters squared) and cigarette smoking status. No significant differences
were observed for all-cause mortality (19.1% vs. 23.6%) and breast cancer-specific
mortality (10.7% vs. 11.3%) between groups with and without DNA samples.
Genes and genetic variants
A total of 24 genes were identified within the human telomere pathway by a literature
review [25–28]. The nine genes (PINX1, POT1, RAD18, TERC, TERF1, TERF2, TERF2IP,
TERT and TNKS) considered as candidate targets in the current study are important genes
coding for proteins involved in telomere maintenance pathway and there is previous
evidence suggesting they are related to cancer development [29]. Totally, 9,768 SNPs are
known for these genes. Potential functional variants were chosen from these genes according
to the criteria: (a) a minor allele frequency ≥5% and heterozygosity ≥0.1 in Caucasians; (b)
>80% homology between human and rat/mouse genomes; (c) located in exons (including
untranslated regions), exon-intron junctions, or promoter regions; (d) previous evidence
indicating a significant functional effect; and (e) previous findings indicating associations
with telomere function or cancer prognosis. Fifty-five genetic variants were selected, and
three SNPs were excluded because they were not in Hardy Weinberg equilibrium or minor
allele frequency was <5%. Finally, 52 variants were evaluated in the final analyses.
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Telomere length was measure by a quantitative PCR (Q-PCR) method described by
Cawthon [30] to determine the relative ratio of telomere (T) repeat copy number to a single-
copy gene (S) copy number (T/S ratio) according to a 5-point standard curve (final
concentrations from 0.125 to 2 ng/ul using mixed human genomic DNA). Variations ranged
from 16 to 21% within the triplicate samples. Genotyping was analyzed by the BioTrove
OpenArray™ system. SNPs that could not be well genotyped on the BioTrove OpenArray™
system were genotyped by TaqMan assays on 384 well plates. Genotype reproducibility was
verified by randomly duplicated DNAs. The overall consistent rates were ranged from 96.4–
97.7% [29]. All assays were performed with the laboratory personnel blinded to the cases
prognostic outcome status. Detailed procedures have been reported previously [29;31].
Statistical analysis
Telomere length was evaluated as a continuous variable or categorized by the median (≥0.73
vs. <0.73) of the study subjects [31]. We also examined the associations between longer
telomere length and survival outcomes by known clinical prognostic factors, including
tumor type (invasive vs. in situ), tumor size (≥2cm vs. <2cm), donated blood status (prior to
vs. post chemotherapy), estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu
status (negative vs. positive). However, for several subgroups, the sample sizes were too
small (<5), yielding unstable results; thus these results are not shown for select subgroups
(including in situ stage, < 2 cm tumor size, donated blood sample after initiation of
chemotherapy). Covariates considered as potential confounders included age at diagnosis
(continuous), race (white vs. other) and family history of breast cancer (no vs. yes). None of
the covariates confounded the association between telomere length and survival outcome;
the final survival model was only adjusted by age at diagnosis as a continuous variable.
Allele frequencies of genetic variants were calculated, and Hardy-Weinberg equilibrium was
determined for each SNP [32]. Genotyping data were examined by a dominant model to
increase statistical power, and improve stability of the results. The Kaplan-Meier and log-
rank test were used to examine the associations between genetic variants, telomere length
and survival outcomes [33]. Cox proportional hazard regression was used to estimate the
hazard ratio (HR) and 95% confidence interval (95%CI) for all-cause and breast cancer-
specific mortality separately.
A backwards elimination strategy was used to evaluate confounding, and build separate
models for each SNP. If eliminating a covariate from the full Cox regression model changed
the main effect of genotyping on survival by 10% or more, the covariate was considered as a
potential confounder, and adjusted for in the survival model. Covariates considered as
potential confounders include age at diagnosis (continuous), race (white vs. other) and
family history of breast cancer (no vs. yes). None of the covariates confounded the
association between the genotyping and survival outcome; the final survival model was only
adjusted by age at diagnosis as a continuous variable. To account for the multiple
comparison problems of 52 SNPs analyzed in the current study, the Bonferroni approach
was used to adjust p-values. All statistical analyses were completed using Statistical
Analysis System 9.0 (SAS Institute, Cary, NC).
RESULTS
When categorized by the median of telomere length in subjects, no substantial relationship
was found between longer telomere length (≥0.73) and overall and breast cancer-specific
mortality (Table I). In a subgroup analysis by menopausal status, a similar non-significant
correlation was found between telomere length and overall and breast cancer-specific
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mortality. No significant associations between longer telomere length and survival were
found in subgroup analyses by tumor type (invasive vs. in situ), estrogen receptor (ER),
progesterone receptor (PR) status (negative vs. positive) and chemotherapy status (prior to
vs. post) (data not shown for select subgroups due to small sample sizes – see Methods).
Significant increased all-cause mortality was observed for longer telomere length among
HER-2/neu negative breast cancer case (HR=1.90, 95%CI: 1.12–3.22). However, no
significant influence of longer telomere length on all-cause or breast cancer specific
mortality was found among HER-2/neu positive cases (Table I). In addition, several
subgroups had small numbers of subjects limiting reliability.
In the age-adjusted Cox models analyzing for 52 genetic variants, there were a total of 5
SNPs showing a significant association with either overall and/or breast cancer survival at
the p < 0.05 significance level (Table II). Carrying the PINX1-33 (rs2277130) G-allele was
significantly associated with increased all-cause mortality (HR=1.45, 95% CI: 1.06–1.98).
Three SNPs (TERF2-03 rs35439397, TERT-14 rs2853677 and TERT-67 rs2853669) were
significantly associated with reduced all-cause mortality. The HRs were, respectively, 0.72
(95% CI: 0.52–0.99), 0.64 (95% CI: 0.48–0.86) and 0.71 (95% CI: 0.54–0.94). A similar
reduced trend for breast cancer-specific mortality was observed for carrying the TERT-14
(rs2853677) T-allele (HR=0.57, 95% CI: 0.39–0.84), while carrying the POT1-18
(rs1034794) T-allele was associated with increased breast cancer specific-mortality
(HR=1.48, 95% CI: 1.00–2.19). However, after Bonferroni adjustment, none of these five
SNPs remain significant. Also, no statistically significant difference was observed for
telomere lengths by the five SNPs. For the other 47 SNPs, no significant correlations with
overall and breast cancer survival were obtained (supplemental Table).
To investigate the cumulative effects of carrying multiple putative risk alleles on overall and
breast cancer survival, we evaluated the combined role of the five SNPs with p<0.05. A
significant dose-response effect was observed with increased number of unfavorable alleles
(PINX1-33 G-allele, POT1-18 T-allele, TERF2-03 GG, TERT-14 CC, and TERT-67 TT
genotypes) and decreased survival after adjusting for age at diagnosis (Table III). Carrying
4–5 unfavorable alleles was associated with a significant increase in all-cause mortality
(HR=2.24, 95% CI: 1.35–3.72) compared to those carrying 0–1 unfavorable alleles. The
HRs for carrying 2–3 and 4–5 unfavorable alleles and breast cancer-specific mortality were,
respectively, 2.15 (95% CI: 1.02–4.51) and 3.53 (95% CI: 1.64–7.62) compared to those
carrying 0–1 unfavorable allele. No significant trend was observed with increased
unfavorable alleles and telomere lengths (Table III).
DISCUSSION
This is a large prospective breast cancer study (1,026 patients) with a follow-up time up to
9.4 years. We did not observe a significant correlation between telomere length and overall
breast cancer survival. However, longer telomere length was significantly associated with
worse prognosis for the subgroup of HER-2/neu negative cases. Our finding is consistent
with one prior study [16], which used the same Q-PCR assay to measure peripheral blood
telomere length as we did in our study; these investigators found long telomeres associated
with reduced survival compared with short telomeres in the subgroup patients with positive
nodes or tumor size >16mm. Most previous studies measuring telomere content or telomere
length in breast tumor tissues by Southern blot or slot blot found the opposite association,
i.e. shorter telomere content was associated with reduced overall survival (reviewed in
[19;34]). Variable methods (terminal restriction fragment (TRF) and Q-PCR) used in
measurement of telomere length can be one reason for the discrepancy, although a good
correlation between TRF and Q-PCR results was reported [35]. The down-regulated
immunological activation observed in cancer patients with long telomere length was another
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explanation [36]. Higher percentage of regulatory T cells indicating decreased immune
response was found in a subset of HER-2/neu negative breast cancer patients [37], which
may lead to less telomere attrition (long telomere length) due to fewer cell divisions, and
reduce antitumor activity. The mechanisms of telomere length maintenance and
compensation in the two types of tissue cells (breast epithelial and hematopoietic) may be
different [16]. Breast epithelial cells are telomerase competent upon mitogenic stimulation,
while hematopoietic cells usually have low but detectable telomerase [38]. Therefore, a
compensation in telomerase expression or a triggered alternate telomeres lengthening
mechanism in patients with poor prognosis may maintain the integrity of telomere length in
blood cell [39].
Five SNPs in four telomere maintenance genes (PINX1, POT1, TERF2 and TERT) were
initially found significantly associated with all-cause or breast cancer-specific mortalities.
Carrying the deleterious PINX1-33 (rs2277130) G-allele or POT1 (rs1034794) T-allele was
correlated with increased all-cause or breast cancer specific-mortality, respectively. Three
favorable alleles in TERF2-03 (A-allele), TERT-14 (T-allele) and TERT-67 (C-allele) were
significantly associated with reduced all-cause mortality. However, these SNPs were no
longer significant after Bonferroni correction for multiple comparisons. Significant dose-
response effects were observed for carrying more unfavorable alleles/genotypes (PINX1-33
G-allele, POT1-18 T-allele, TERF2-03 GG, TERT-14 CC, and TERT-67 TT genotypes) and
increased overall and breast cancer-specific mortality. These data suggest that multiple
genetic variants in telomere maintenance genes may provide useful information to improve
prediction of breast cancer survival.
Previous studies suggest biological mechanisms for the effects of genetic changes in
telomere maintenance genes on telomere function and cancer prognosis, including breast
cancer. The potential impact of genetic variants was demonstrated in a study that found
telomerase activity significantly increased in carriers of the TERT-67 TT genotype
compared to those with the CC genotype (p=0.03) [40]. While there are no studies that
directly link mRNA levels to SNPs of telomere maintenance genes, changes in expression
have been associated with telomere length, tumor stage (POT1) [41], severity of breast
cancer progression (TERF2) [15], recurrent disease (TERT) [42] and prediction of overall
and disease-free survival (TERT) [15]. In other studies, two mutations in PINX1 were found
to force TERT accumulation within the nucleolus [43] and one SNP in TERF2 (rs3785074)
displayed significant associations with histologic grade and negative ER status [17]. Taken
together, these results suggest that it is biologically plausible for SNPs in telomere pathway
genes to impact on gene expression and function.
The strengths of the current study includes the population-based study design with a
relatively large sample size, the longer follow-up time with detailed survival outcomes, a
moderate number of genes/SNPs within the telomere pathway and an intermediate
phenotype marker (telomere length) being examined simultaneously. Several genes in the
telomere pathway were found to be separately associated with overall (PINX1, TERF2 and
TERT) or breast cancer-specific survival (POT1 and TERT) indicating that the genetic
variants may have potential value as prognostic markers. These data are important evidence
for understanding the biological mechanisms of breast cancer prognosis, although their
effects need confirmation in independent studies. Genetic variant within genomic DNA are
stable and easily analyzed from the perspective of clinical practice compared to RNA or
protein markers. This advantage makes the establishment of robust genetic predictive
models of breast cancer survival feasible in the future. One potential drawback of the current
study was that only the most common SNPs in telomere relevant genes were examined, and
the effects of other variations with rare frequencies were not considered. We were unable to
adequately evaluate the impact of SNPs and telomere length on breast cancer mortality
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categorized by several clinical prognostic factors due to small sample size and/or missing
data during the medical record abstraction. Another limitation was lack of biological
functional studies on candidate geneticvariants and no telomerase activities were directly
evaluated.
In summary, we found five genetic variants in telomere pathway genes (PINX1, POT1,
TERF2 and TERT) were significantly associated with breast cancer survival in a well-
designed population-based study. A significant dose-response effect of carrying more
unfavorable variant alleles and increased mortality provides critical data on the role of
genetic polymorphisms in breast cancer prognosis. Longer telomere length was only
correlated with all-cause mortality among the subgroup of HER-2/neu negative breast cancer
patients. Independent studies to evaluate these findings are necessary to exclude potential
false positive associations. Relevant functional studies and direct measurement of
telomerase activity will clarify the link between telomere pathway genes and breast cancer
survival, and contribute to clinical prediction of prognosis.
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